Literature DB >> 11777551

Chemokine receptor expression on B cells and effect of interferon-beta in multiple sclerosis.

Torben L Sørensen1, Hanne Roed, Finn Sellebjerg.   

Abstract

We investigated the B-cell expression of chemokine receptors CXCR3, CXCR5 and CCR5 in the blood and cerebrospinal fluid (CSF) from patients in relapse of multiple sclerosis (MS) and in neurological controls. Chemokine receptor expression was also studied in interferon-beta-treated patients with relapsing-remitting or secondary progressive MS. We observed significantly higher expression of CXCR3 on B cells in the CSF in active MS than in controls. Patients with active MS also had higher B-cell expression of CCR5 in blood. No major differences between RRMS and SPMS patients were detected, and chemokine receptor expression was not affected by interferon-beta treatment.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11777551     DOI： 10.1016/s0165-5728(01)00453-2

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  9 in total

1.  Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis.

Authors:  S Hosomi; N Oshitani; N Kamata; M Sogawa; H Okazaki; T Tanigawa; H Yamagami; K Watanabe; K Tominaga; T Watanabe; Y Fujiwara; K Maeda; K Hirakawa; T Arakawa
Journal:  Clin Exp Immunol       Date:  2010-11-19       Impact factor: 4.330

2.  High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.

Authors:  Martin Diebold; Edoardo Galli; Andreas Kopf; Nicholas S R Sanderson; Ilaria Callegari; Pascal Benkert; Nicolás Gonzalo Núñez; Florian Ingelfinger; Stefan Herms; Sven Cichon; Ludwig Kappos; Jens Kuhle; Burkhard Becher; Manfred Claassen; Tobias Derfuss
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-26       Impact factor: 12.779

3.  Complete ablation of tumor necrosis factor decreases the production of IgA, IgG, and IgM in experimental central nervous system tuberculosis.

Authors:  Ngiambudulu M Francisco; Nasiema Allie; Boipelo Sebesho; Bernhard Ryffel; Muazzam Jacobs
Journal:  Iran J Basic Med Sci       Date:  2020-05       Impact factor: 2.699

4.  Optic neuritis: chemokine receptor CXCR3 and its ligands.

Authors:  T L Sørensen; H Roed; F Sellebjerg
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

5.  Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Maren Henneken; Thomas Dörner; Gerd-Rüdiger Burmester; Claudia Berek
Journal:  Arthritis Res Ther       Date:  2005-06-22       Impact factor: 5.156

Review 6.  Actions of Thyroid Hormone Analogues on Chemokines.

Authors:  Paul J Davis; Gennadi V Glinsky; Hung-Yun Lin; Shaker A Mousa
Journal:  J Immunol Res       Date:  2016-07-17       Impact factor: 4.818

7.  Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells.

Authors:  Maija Saraste; Tarja-Leena Penttilä; Laura Airas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-10-24

8.  Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

Authors:  Mohsen Khademi; Ann M Dring; Jonathan D Gilthorpe; Anna Wuolikainen; Faiez Al Nimer; Robert A Harris; Magnus Andersson; Lou Brundin; Fredrik Piehl; Tomas Olsson; Anders Svenningsson
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

9.  Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Rikke Ratzer; Fredrik Piehl; Mohsen Khademi; Tomas Olsson; Per Soelberg Sørensen; Finn Sellebjerg
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.